Physician profile
Paul T Smith
NPI 1861595720
$30,178.17
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,532 · 2021: $4,267 · 2022: $5,096 · 2023: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26,485.59 | 2019-2022 | |
| Viiv Healthcare Company | $1,133.67 | 2019-2023 | Dovato |
| Merck Sharp & Dohme LLC | $728.04 | 2019-2023 | Recarbrio |
| Janssen Products, Lp | $227.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $199.99 | 2019-2020 | |
| Medtronic Vascular, INC. | $193.31 | 2019 | |
| Glaxosmithkline, LLC. | $193.12 | 2019-2022 | |
| Janssen Biotech, INC. | $179.03 | 2019-2022 | |
| Tepha INC | $152.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.69 | 2019-2020 | |
| Lilly USA, LLC | $138.01 | 2019-2022 | |
| Emd Serono, INC. | $133.95 | 2019-2022 | |
| United Therapeutics Corporation | $100.00 | 2020 | |
| Theratechnologies INC. | $60.13 | 2019-2020 | |
| Abbvie INC. | $29.23 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $19.63 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $16.07 | 2022 | |
| Pfizer INC. | $13.03 | 2022 | |
| Oxford Immunotec USA INC | $11.76 | 2022 | |
| Sanofi Pasteur INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.